Micro Labs: Delivering Value through High Quality Products

Currently, the Indian pharmaceuticals market is the third largest in terms of volume and the thirteenth largest in terms of value and is expected to grow to a whooping US$ 100 billion by 2025. Driven by increasing consumer spending, rapid urbanization, and raising healthcare insurance, India enjoys a significant position in the worldwide pharmaceuticals sector.
Micro Labs Limited, a multi-faceted healthcare organization, has contributed greatly in placing India amongst the top pharmaceutical markets of the world. Micro Labs, aided with their proficient marketing team, state-of-the-art manufacturing facilities and top-notch R&D centres, is one of the fastest growing transnational healthcare organizations. Moreover, the company is backed by strong distribution network and path-breaking research which resulted in them being ranked 13th among Prescriptions according to SMSRC Jan 18’ and 19th in Sales as per AWACS MAT Jan 18’.
A frontrunner in the pharmaceutical industry, Micro Labs is built around strong believes in quality, ethics, customer focus, and respect for people. Their vision is to be a leader in the development, manufacture, and sales of premium pharmaceutical products.
Dedicated to manufacturing medicine of the highest standard and marketing it at affordable prices across the globe, Micro Labs is poised to achieve unparalleled status in the global pharmaceutical industry. Their brand portfolio includes some of the topmost brands in various specialties like Cardiology, Diabetology, Anti-infectives, Ophthalmology, Pain, etc. Additionally, the company is involved at social and environmental fronts striving to be a model corporate citizen.
A True Entrepreneur
Dilip Surana, the Chairman and Managing Director of Micro Labs, is the man behind the company’s unmatched success. With over 20 years of rich experience in pharmaceuticals, Dilip currently holds the 73rd position among the 100 Richest Indians.
When he took over Micro Labs from the reigns of his father, Mr. G. C. Surana, hardly anyone could assume the stupendous success he would achieve. “My father’s ability to pick up the chemistry of a drug was amazing. For him there was no holiday. He lived and breathed business and inculcated the same values in me. Even during my high school days, he made sure I learn the trade, starting from the lowest rung,” says Dilip Surana.
The growth of Micro Labs has a lot to do with Mr. Dilip’s vision and passion. He consistently brings in fresh ideas and under his expert guidance, Micro Labs became one of the few companies in the mid-1980s to have separate strategic business units that focused on areas such as cardiology, neurology, dermatology and nephrology.
Due to his remarkable efforts in the success of Micro Labs, Dilip Surana has been a regular participant in various international seminars and summits relating to pharma industry. He is instrumental in inducting Senior Pharma veterans in the company while bringing in the much needed professionalism in the company.
Under Mr. Dilip’s leadership, the company is rightly regarded as a pioneer in many ways as it has introduced various molecules in India for the very first time. He has also established world class state-of-the-art research and manufacturing facilities covering Active Pharmaceutical Ingredients (APIs) and finished dosage forms as well as infrastructure for new drug discovery.
Today, with Dilip’s efforts, the company is committed to carry out world-class research that develops bio-equivalent generics. However, in spite of all his success, this kindhearted and visionary chairman of Micro Labs has a simple living attitude.
When you’re an entrepreneur, everything’s on the line. People don’t realize that. You believe so much in it, you’re willing to risk everything, as I did. It’s hard to lose everything and start over again. But I think that’s what separates successful entrepreneurs from unsuccessful ones — the ability to fall off your bike, get back on and keep riding. It’s very hard to achieve success but it’s even harder to maintain success. Trying to expand and get bigger even are more challenging” says Dilip Surana.
An Inspirational Voyage
The story of Micro Labs cannot unfold without mentioning their inspirational founder and leader Mr. G. C. Surana. With a humble beginning as a Pharmaceutical Distributor in Bangalore, Mr. Surana began a marketing and distributions agency for a pharmaceutical company. With his valuable experience and sheer dedication towards hard work, he founded Micro Labs Limited in 1973.
Mr. Surana’s perseverance and leadership has led Micro Labs from a modest pharmaceutical manufacturing company to its current success as a leading name in the pharmaceutical industry. Over the years, Micro Labs has reinforced its position as an industry leader and was proud to unveil their state-of-the-art ophthalmic plant, the first of its kind in Asia, in July 2006.
Today, Micro Labs is a multi-faceted organization with an annual turnover of Rs.2700 Crore, including exports that contribute Rs. 920 Crore. The distinguished attributes of the company are the 14 oral formulation plants including an injectable unit; a bulk drug facility, offices located overseas, and a strong distribution network. Their marketing efforts span into 20 divisions, with each division specialized to cater various therapeutic segments. The organization’s most important component, however, remains its 9200 dedicated employees.
With state-of-the-art facilities and 3 R&D centers designed to international standards, Micro Labs is poised to become a respected global brand in the pharmaceutical field and highlight our nation’s growing reputation in the Global scenario.
Outstanding Products and Services
Micro Labs’ initiation into the pharmaceutical business began with a number of quality products in niche healthcare areas like anti-bacterial compounds, antiseptics and vitamins. The company has since created a strong presence in the healthcare market owing to their stringent quality control and distribution standards combined with innovative products.
Under the expert leadership of Dilip, Micro Labs have evolved into a diversified pharmaceuticals manufacturing company with products ranging from oral solids, topicals to injectibles. The company has 14 plants that have been contributing significantly to the healthcare needs of the domestic market for over three decades. Micro Labs has a long term commitment to developing Bio-equivalent Generics with the help of world class research and high quality standards. Their main focus remains on developing new formulations in various dosage forms including solid dosage, liquid dosage, sterile preparations, injectables, creams, ointments, etc.
The continuous strive for perfection has led Micro Labs towards building state-of-the-art facilities which has assisted their growth in the regulated markets. The company’s vision to create a Vertically Integrated Organization that offers a wide range of products has led them to set up their very own API Manufacturing facilities.
Dilip has instilled the most stringent quality standards in his pharmaceutical enterprise. As a result, Micro Labs has to its credit, all the international regulatory approvals including US FDA, UK MHRA, MCC, South Africa, Health Canada, WHO, Geneva TGA, Australia Medsafe, New Zealand PAHO (USA), IDA (Netherlands) and many regulatory bodies of emerging markets reflecting the high standards of quality and regulatory compliance of research and manufacturing facilities.
Future Endeavors
Micro Labs has been in a continuous stage of growth ever since the founding years and continues to chart its course as a leader in the pharmaceutical vertical. The company has presence in over 40 countries with ground level operations in over 15 countries, exporting all major dosages on most of the therapeutic segments.
They have started looking at in-licensing locally, whereas internationally they have more of a joint venture approach. They are doing a lot of molecule-to-molecule as well as country-to-country business. As they aim to be associated with quality, their focus will be on niche generics and retroviral drugs.

Related Posts